BPX 601

Drug Profile

BPX 601

Alternative Names: BPX601

Latest Information Update: 01 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bellicum Pharmaceuticals
  • Class CAR-T cell therapies; Immunotherapies
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Pancreatic cancer

Most Recent Events

  • 21 Feb 2017 Phase-I clinical trials in Pancreatic cancer (Inoperable/Unresectable) in USA (IV) (NCT02744287)
  • 16 Feb 2017 ARIAD Pharmaceuticals has been acquired by Takeda
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top